Hepatology ():10.1097/HEP.0000000000001549, November 4, 2025. | DOI: 10.1097/HEP.0000000000001549
Ghany, Marc G.; Pan, Calvin Q.; Lok, Anna S.; Feld, Jordan J.; Lim, Joseph K.; Wang, Su H.; Kim, Arthur Y.; Tang, Amy S.; Nguyen, Mindie H.; Naggie, Susanna; Sulkowski, Mark S.; Rodriguez-Baez, Norberto; Chen, J.; Murad, M. Hassan; Mohammad, Khaled S.; Terrault, Norah A.
This guideline is currently available as an accepted manuscript. The final version of record will be posted upon publication.
Background and Aims
Accumulating data related to prevention, surveillance and treatment of chronic hepatitis B (CHB) provided the impetus for this updated guideline, using the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach.
Methods
The guideline was developed in compliance with the National Academy of Medicine standards. The guideline panel developed structured questions following the Population, Intervention Comparison, Outcomes (PICO) framework. The panel addressed 6 PICO questions covering prevention (maternal to infant transmission and horizontal transmission), surveillance for liver cancer (among hepatitis B surface antigen positive (HBsAg) persons co-infected with hepatitis C virus, hepatitis D virus and/or human immunodeficiency viruses and after HBsAg loss) and treatment (HBsAg positive persons in immune-tolerant or indeterminate phases as well as withdrawal of antiviral therapy), providing evidence-based recommendations on these topics. Four systematic reviews of the literature were conducted, and two existing systematic reviews were utilized to support the recommendations in this practice guideline.
Conclusions
This evidence-based guideline provides updated recommendations to optimize the care of persons with CHB.
Additional Resources
Commentary - AASLD Practice Guideline on Treatment of Chronic Hepatitis B (2025 Update)